Cargando…

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

BACKGROUND: To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). METHODS: TECOS randomized 14,671 participants with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nauck, Michael A., McGuire, Darren K., Pieper, Karen S., Lokhnygina, Yuliya, Strandberg, Timo E., Riefflin, Axel, Delibasi, Tuncay, Peterson, Eric D., White, Harvey D., Scott, Russell, Holman, Rury R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719352/ https://www.ncbi.nlm.nih.gov/pubmed/31481069 http://dx.doi.org/10.1186/s12933-019-0921-2

Ejemplares similares

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Progression of glucose‐lowering diabetes therapy in TECOS
por: Bethel, M. Angelyn, et al.
Publicado: (2018)

Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease
por: Stevens, Susanna R., et al.
Publicado: (2022)

Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS
por: Ghosal, Samit, et al.
Publicado: (2016)

Validation of the WATCH‐DM and TRS‐HF(DM) Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis
por: Segar, Matthew W., et al.
Publicado: (2022)

Re‐adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study‐level meta‐analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase‐4 (DPP‐4) inhibitors
por: Scirica, Benjamin M., et al.
Publicado: (2022)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
por: Bethel, M. Angelyn, et al.
Publicado: (2023)

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
por: Baggio, Laurie L., et al.
Publicado: (2020)

Impact of Ezetimibe on New‐Onset Diabetes: A Substudy of IMPROVE‐IT
por: Shah, Nishant P., et al.
Publicado: (2023)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

A rare coexistence of non-functional adrenocortical carcinoma and multicentric papillary thyroid microcarcinoma: a case report
por: Karakose, Melia, et al.
Publicado: (2013)

The Contributions of Gamma Probe to Lesion Detectability and Surgical Safety in Recurrent Thyroid Cancer at Risk
por: Gültekin, Salih Sinan, et al.
Publicado: (2013)

Additive effects of atorvastatin combined with sitagliptin on rats with myocardial infarction: a pilot study
por: Ke, Xiao, et al.
Publicado: (2017)

Sitagliptin-induced hemolysis
por: Bekur, Ragini, et al.
Publicado: (2010)

Sitagliptin-Associated Angioedema
por: Gosmanov, Aidar R., et al.
Publicado: (2012)

Comparison of different methods used in drugs of abuse for sample validity testing including pH methods, specific gravity methods, TECO™ Drug Adulteration Test Strip and oxidant assay
por: Mina, Ashraf, et al.
Publicado: (2021)

Medical hypothesis: can gonadotropins influence thyroid volume in women with PCOS?
por: Cakir, Evrim, et al.
Publicado: (2012)

Comparison of regression imputation methods of baseline covariates that predict survival outcomes
por: Solomon, Nicole, et al.
Publicado: (2020)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
por: Cho, Yong Kyun
Publicado: (2018)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

2159. Methodological Threats to the Standardized Infection and Standardized Antimicrobial Administration Ratios
por: Lofgren, Eric, et al.
Publicado: (2018)

Fixed drug eruption to sitagliptin
por: Gupta, Mrinal, et al.
Publicado: (2015)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
por: Sayari, Saba, et al.
Publicado: (2018)

Struma ovarii presenting with Hashimoto's thyroiditis: a case report
por: Bozkurt, Nujen Çolak, et al.
Publicado: (2011)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
por: Nauck, Michael, et al.
Publicado: (2014)

Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
por: Lopes, Renato D, et al.
Publicado: (2013)

Congenital leptin deficiency and thyroid function
por: Paz-Filho, Gilberto, et al.
Publicado: (2009)

The role of BRD7 in embryo development and glucose metabolism
por: Kim, Yoo, et al.
Publicado: (2016)

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
por: Arnolds, Sabine, et al.
Publicado: (2010)

Sitagliptin: Is It Effective in Routine Clinical Practice?
por: Mohan Dallumal, Rita, et al.
Publicado: (2015)

Unresponsive Intractable Chronic Headache With Sitagliptin
por: Zaghloul, Ahmed, et al.
Publicado: (2018)

Is sitagliptin effective for the treatment of COVID-19?
por: Memiş, Hasan, et al.
Publicado: (2022)

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial
por: Harumi Higuchi dos Santos, Marilia, et al.
Publicado: (2017)

Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts
por: Lee, Tsung-Ming, et al.
Publicado: (2015)

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
por: Engel, S S, et al.
Publicado: (2010)

Spectroflourometric and Spectrophotometric Methods for the Determination of Sitagliptin in Binary Mixture with Metformin and Ternary Mixture with Metformin and Sitagliptin Alkaline Degradation Product
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted rats
por: Lee, Tsung-Ming, et al.
Publicado: (2016)

Rhinorrhea, cough and fatigue in patients taking sitagliptin
por: Baraniuk, James N, et al.
Publicado: (2010)

Hypoglycemia associated with off-label sitagliptin use
por: Whitley, Heather P, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_hit4o1esuegcp2cjb9mb2g9tqt